Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.immatics biotechnologies has started a global multicenter, randomized, controlled IMPRINT Phase III study with the vaccination of the first patient with their lead cancer vaccine IMA901 as a treatment for renal cell carcinoma (RCC).
Subscribe to our email newsletter
The trial willo involve around 330 patients throughout the US and Europe.
The trial intends to show the overall survival benefit of IMA901 in conjunction with standard first-line therapy in RCC patients.
The primary endpoint of the Phase III study is overall survival in patients receiving IMA901 in combination with sunitinib versus sunitinib alone.
However, the secondary endpoints include progression-free survival, safety and tolerability, and cellular immunomonitoring to assess the T-cell response to the peptides contained in IMA901.
immatics CMO Carsten Reinhardt said they look forward to confirming the positive overall survival data seen in the phase II study as advanced renal cell cancer still has high unmet medical need.
immatics CEO Paul Higham said an overall survival benefit combined with a stable and easy to manufacture formulation would make IMA901 an important breakthrough in the development of therapeutic cancer vaccines.